

# Proteomic Alterations in Response to Hypoxia Inducible Factor $2\alpha$ in Normoxic Neuroblastoma Cells

Flora Cimmino,<sup>\*,†,‡</sup> Lucia Pezone,<sup>‡,§</sup> Marianna Avitabile,<sup>†,‡</sup> Luca Persano,<sup>||</sup> Monica Vitale,<sup>†,‡</sup> Mauro Sassi,<sup> $\perp$ </sup> Silvia Bresolin,<sup>#</sup> Valentina Serafin,<sup>#</sup> Nicola Zambrano,<sup>†,‡</sup> Andrea Scaloni,<sup> $\perp$ </sup> Giuseppe Basso,<sup>#</sup> Achille Iolascon,<sup>†,‡</sup> and Mario Capasso<sup>†,‡</sup>

<sup>†</sup>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", via Pansini, 5, 80131 Naples, Italy

<sup>‡</sup>CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore 486, 80145 Naples, Italy

<sup>§</sup>Scuola di Medicina e Chirurgia, Università degli Studi di Verona, 37129 Verona, Italy

<sup>II</sup>Istituto di Ricerca Pediatrica Città della Speranza - IRP, 35121 Padua, Italy

<sup>1</sup>Proteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80147 Naples, Italy

<sup>#</sup>Dipartimento di Salute della Donna e del Bambino, Università degli Studi di Padova, 35128 Padua, Italy

**S** Supporting Information



**ABSTRACT:** Hypoxia inducible factor (HIF)- $2\alpha$  protein expression in solid tumors promotes stem-like phenotype in cancer stem cells and increases tumorigenic potential in nonstem cancer cells. Recently, we have shown that HIF- $1/2\alpha$  gene expression is correlated to neuroblastoma (NB) poor survival and to undifferentiated tumor state; HIF- $2\alpha$  protein was demonstrated to enhance aggressive features of the disease. In this study, we used proteomic experiments on NB cells to investigate HIF- $2\alpha$ downstream-regulated proteins or pathways with the aim of providing novel therapeutic targets or bad prognosis markers. We verified that pathways mostly altered by HIF- $2\alpha$  perturbation are involved in tumor progression. In particular, HIF- $2\alpha$  induces alteration of central metabolism and splicing control pathways. Simultaneously, WNT, RAS/MAPK, and PI3K/AKT activity or expression are affected and may impact the sensitivity and the intensity of HIF- $2\alpha$ -regulated pathways. Furthermore, genes coding the identified HIF- $2\alpha$ -related markers built a signature able to stratify NB patients with unfavorable outcome. Taken together, our findings underline the relevance of dissecting the downstream effects of a poor survival marker in developing targeted therapy and improving patient stratification. Future prospective studies are needed to translate the use of these data into the clinical practice.

**KEYWORDS**: hypoxia inducible factor  $2\alpha$ , neuroblastoma, proteomics, patient stratification

# INTRODUCTION

Hypoxia-inducible factors (HIF-1 $\alpha$ , HIF-2 $\alpha$ ) are key mediators of the cellular response to low oxygen concentrations (hypoxia). In the absence of oxygen, they are stabilized against degradation and thereby coordinate hypoxia adaptation through the expression of several target genes involved in neo-angiogenesis,

glucose transport, and metabolism, which are required for tumor

Received: May 19, 2016

growth and metastasis formation.<sup>1</sup> HIF-1 $\alpha$  participates in the initial response to hypoxia being most active during short periods (2–24 h) of intense hypoxia or anoxia (<0.1% O<sub>2</sub>). Conversely, HIF-2 $\alpha$  is active under mild hypoxia (<5% O<sub>2</sub>) or normoxia.<sup>2,3</sup> Moreover, an hypoxia-independent regulation appears probable in the latter case because there are examples of genes whose expression is regulated by HIF-2 $\alpha$  in cells grown under normoxic conditions.<sup>4,5</sup>

HIF-2 $\alpha$  protein expression in tumor perivascular regions promotes stem-like phenotype in cancer stem cells and increases tumorigenic potential in nonstem cancer cells.<sup>6–8</sup> HIF-2 $\alpha$ -driven molecular mechanisms in tumor development are different. For example, HIF-2 $\alpha$  overexpression as well as the deletion of EPAS1 (HIF-2 $\alpha$  coding gene) increases the growth of KRAS-driven lung tumors in mice.<sup>9</sup> In particular, aberrant HIF-2 $\alpha$  levels increase the expression of VEGFA and SNAIL, thus promoting angiogenesis and tumor invasion. By contrast, the complete loss of HIF-2 $\alpha$  reduces the expression of the tumor suppressor Scgb3a1, a HIF-2 $\alpha$  target gene.<sup>9</sup> Thus the pharmacological inhibition of HIF proteins for cancer treatment, whether targeting HIF-1 $\alpha$  and HIF-2 $\alpha$  together or individually, may not be straightforward. Targeting the key actors of oncogenic transformation downstream to HIF-2 $\alpha$  may be a fascinating way to improve the efficacy of tumor-focused therapies.<sup>10</sup>

To establish the protein networks regulated by HIF-2 $\alpha$  and to speculate which HIF-2 $\alpha$ - related proteins may be therapeutic targets or poor prognosis markers, we have focused on neuroblastoma (NB), a childhood malignancy of the developing sympathetic nervous system. NB patients present widespread hematogenous-based metastases in over 50% of cases.<sup>11</sup> Recently, introduced targeted therapies for NB patients include the small molecule inhibitor Crizotinib, which targets the receptor tyrosine kinase anaplastic lymphoma kinase (ALK); this drug have shown good toleration results in a recent Phase 1 dose-escalation trial.<sup>12</sup> Moreover, monoclonal antibody targeting the disialoganglioside GD2 included in an immunotherapeutic regimen resulted in a dramatic increase in event-free survival from 46 to 66%.<sup>13</sup> However, despite these recent advances, most high-risk NB patients die as result of the disease.<sup>11</sup> HIF-2 $\alpha$ knockout in NB samples impairs tumorigenesis and leads to a less aggressive/more differentiated phenotype.<sup>14</sup> Recently, we have shown HIF-1/2 $\alpha$  gene expression is correlated to NB poor survival and to undifferentiated tumor state.<sup>5</sup> Interestingly, we demonstrated that HIF-2 $\alpha$  overexpression enhances the aggressive features of NB cells by means of the expression of pro-invading and antiadhesive CD55 antigen.<sup>15</sup>

In this study, we aimed to unravel the molecular mechanisms that might support HIF-2 $\alpha$ -induced tumor progression by highlighting the proteomic changes induced by HIF-2 $\alpha$  perturbation in NB cells. To this purpose, a combined 2D-DIGE/nanoLC-ESI-LIT-MS/MS approach and reverse-phase protein array (RPPA) were used. Moreover, we verified that the expression of genes coding the identified HIF-2 $\alpha$ -related proteins generates a signature able to stratify NB patients in different risk subgroups.

#### EXPERIMENTAL PROCEDURES

#### **Cell Cultures**

The human SHSY5Y-pcDNA and SHSY5Y-HIF-2 $\alpha$  NB cell clones were generated as already described.<sup>15</sup> The cells were grown in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 kU/L penicillin, and

100 mg/L streptomycin at 37  $^\circ\text{C}$  in 5%  $\text{CO}_2$  in a humidified atmosphere.

#### **Protein Fractionation**

Cellular pellets from SHSY5Y-pcDNA and SHSY5Y-HIF-2 $\alpha$  NB clones were incubated in ice-cold lysis buffer (250 mM sucrose, 3 mM imidazole, pH 7.4, and 1 mM EDTA) in the presence of a protease inhibitor cocktail (Complete Mini EDTA-free, Roche) and were disrupted by 8–10 passes through a 22-guage needle. Then, they were centrifuged at 16 000g for 20 min at 4 °C. This procedure allowed us to enrich the corresponding nuclear fractions; protein extraction was then performed as already described.<sup>16</sup>

#### **Cy-Dye Labeling**

After adjusting the pH value to 8.5, protein extracts ( $50 \mu g$ ) from three biological replicates of SHSY5Y-pcDNA cells and three replicates of SHSY5Y-HIF-2 $\alpha$  cells were labeled separately with 400 pmol of Cy3 and Cy5. A pool composed of equal amounts of all samples (six in number) was prepared, labeled with Cy2, and used as a standard on all gels. Labeling reactions were performed on ice in the dark for 30 min and were quenched by the addition of 1 mM lysine (final concentration). Samples were mixed and the final volume was adjusted to 450  $\mu$ L with 7 M urea, 2 M tiourea, and 3% CHAPS. The samples were supplemented with 0.5% carrier ampholytes pH 3–11 (GE Healthcare, Milan, Italy) and 1% bromophenol blue.

#### 2-D Gel Electrophoresis and DIGE Analysis

For 2D-DIGE, IPG strips (length, 24 cm; thickness, 0.5 mm) (GE Healthcare) nonlinear pH gradient range 3-11 were passively rehydrated with 150  $\mu$ g of tripartite-labeled sample (50  $\mu$ g for each labeled sample and 50  $\mu$ g internal standard) in the dark overnight. IEF was performed using an IPGphor II apparatus (GE Healthcare) at 20 °C with a maximum current setting of 50  $\mu$ A/strip in the dark. IEF run conditions were the following: linear voltage up to 200 V in 1 h, up to 1000 V in 1 h, up to 1500 V in 1 h, up to 3500 V in 1 h, constant voltage to 3500 V for 3 h, linear voltage up to 5000 V in 1 h, constant voltage to 5000 V for 4 h, linear voltage up to 8000 V for 1 h, and constant voltage to 8000 V, until the total product time × voltage applied was 76 000 Vh for each strip. The strips were equilibrated in 6 M urea, 2% SDS, 20% glycerol, and 0.375 M Tris-HCl (pH 8.8) for 15 min in the dark in the presence of 0.5% w/v DTT and then in the presence of 4.5% w/v iodacetamide in the same buffer for an additional 15 min. Equilibrated IPG strips were transferred onto 11% polyacrylamide gels, within low-fluorescence glass plates (ETTAN-DALT 6 system, GE Healthcare). Second-dimension SDS-PAGE was performed by using a DALT II electrophoresis unit (GE Healthcare) at 2 W/gel for 12 h. Gels were scanned with a Typhoon 9400 variable mode imager (GE Healthcare) using appropriate excitation/emission wavelengths for Cy2 (488/520 nm), Cy3 (532/580 nm), and Cy5 (633/670 nm). Images were acquired in the Image-Quant software (GE Healthcare) and analyzed by using the DeCyder 6.0 software (GE Healthcare).<sup>16</sup> A DeCyder differential in-gel analysis (DIA) module was used for spot detection and pairwise comparison of each sample (Cy3 and Cy5) to the Cy2 standard present in each gel. The DeCyder biological variation analysis (BVA) module was used to simultaneously match all of the proteomic maps from the gels and to calculate average abundance ratios and p values across the triplicate sets of samples (Student's t test).

For preparative gel electrophoresis, 1 mg of unlabeled sample was used to passively rehydrate the IPG strips. The first and second dimension runs were conducted as described above. After 2-D electrophoresis, the separated proteins were visualized using a highly sensitive fluorescent stain (SYPRO Ruby Protein Gel Stain, Life Technologies). In brief, the resolved polypeptides were fixed in 7% acetic acid/50% methanol solution for 30 min and stained overnight. The gels were washed in 7% acetic acid/ 10% methanol for 30 min and in  $H_2O$  for 30 min. Finally, gels were scanned as mentioned above.

#### **Mass Spectrometry Analysis and Protein Identification**

Protein spots were excised from the preparative gel, alkylated, digested with trypsin, and identified as previously reported.<sup>1</sup> Peptide mixtures were desalted by  $\mu$ Zip-TipC18 (Millipore, USA) using 50% v/v acetonitrile/5% v/v formic acid as eluent before nanoLC-ESI-LIT-MS/MS analysis. Tryptic digests were analyzed using an LTQ XL mass spectrometer (Thermo, USA) equipped with a Proxeon nanospray source connected to an Easy nanoLC (Thermo, USA). Peptide mixtures were separated on an Easy C<sub>18</sub> column (10–0.075 mm, 3  $\mu$ m) (Thermo, USA).<sup>16</sup> Mobile phases were 0.1% v/v aqueous formic acid (solvent A) and 0.1% v/v formic acid in acetonitrile (solvent B), running at total flow rate of 300 nL/min. Linear gradient was initiated 20 min after sample loading; solvent B ramped from 5 to 35% over 15 min, from 35 to 95% over 2 min. Spectra were acquired in the range m/z 400–1800. Acquisition was controlled by a datadependent product ion scanning procedure over the three most abundant ions, enabling dynamic exclusion (repeat count 1 and exclusion duration 60 s); mass isolation window and collision energy were set to m/z 3 and 35%, respectively. MASCOT search engine version 2.2.06 (Matrix Science, U.K.) was used to identify protein spots from a nonredundant human database (NCBI downloaded June 2014), using nanoLC-ESI-LIT-MS/MS data. Database searching was performed selecting trypsin as proteolytic enzyme, a missed cleavages maximum value of 2, and Cys carbamidomethylation and Met oxidation as fixed and variable modification, respectively. Candidates with at least two assigned peptides with an individual MASCOT score >25, both corresponding to p value <0.05 for a significant identification, were further evaluated by the comparison with their calculated mass and pI values using the experimental data obtained from 2D-DIGE.

# **Data Mining**

Differentially represented proteins between HIF-2 $\alpha$ -overexpressing (HIF-2 $\alpha$ ) and control cells (pcDNA) were classified using the DAVID 2.1 beta annotation system (https://david. ncifcrf.gov/content.jsp?file=/ease/ease1.htm&type=1). This tool adopts the Fisher exact test to measure the gene enrichment in annotation terms. A *p* value <0.05 was considered statistically significant. We performed a gene enrichment analysis that included biological process and Kegg pathways terms.

# **Oil Red Staining**

Eighty thousand cells were seeded on treated glass slide (BD Falcon, REF 354108). The day after, the cells were fixed in 10% formalin for 10 min and then rinsed three times in PBS. Slides were then placed in Oil Red O (Lipid Stain) solution for 10 min, rinsed in tap water, and counterstained with hematoxylin for 1 min (Abcam). Sections were then mounted in Fluoromount-G and coverglassed. The images were acquired using a DMI4000B microscope (Leica Mycrosystem).

# Western Blotting

For DIGE data validation, equal amounts of nuclear extracts (25  $\mu$ g) were loaded onto 8 or 12% polyacrylamide gels and

transferred to PVDF membrane (Biorad) as described.<sup>16</sup> Membranes were incubated under constant shaking with the primary antibodies reported in Table S1 overnight at 4 °C. H3 was used as loading control. For phosphoproteomics data validation, total protein extracts were isolated in lysis buffer as previously described.<sup>19</sup> Membranes were incubated under constant shaking with primary antibodies reported in Table S1 overnight at 4 °C.  $\beta$ -Actin (Sigma-Aldrich) was used as loading control. Membranes were next incubated with peroxidase (HRP)-conjugated antirat, antimouse, antirabbit, and antigoat antibodies (GE Healthcare). All bands were visualized using ECL kit SuperSignal West Pico Chemiluminescent Substrate (Pierce), acquired with a GelDoc 2000 system (Bio-Rad), and quantified by densitometry measurements using the Quantity One 4.5 tool (Bio-Rad).

# **Reverse-Phase Protein Array (RPPA)**

Reverse-phase protein array analysis was performed as previously described with few adjustments.<sup>20</sup> In brief, protein lysates were printed in three-point dilution curves in quadruplicate on nitrocellulose-coated glass slides (ONCYTE Nitrocellulose Film Slides, Grace BioLabs) with the 2470 Arrayer (Aushon BioSystems). Slides were stained for total protein content (Fast Green FCF; Sigma-Aldrich) and with 79 validated primary antibodies (Table S2) on an automated slide stainer (Dako Autostainer Plus, Dako-Cytomation). Signal amplification stage was performed through the incubation with streptavidinbiotin-HRP complexes, VECTASTAIN Elite ABC Kit (VECTOR) 20  $\mu$ L/mL in PBS 0.1% BSA for 15 min, followed by the incubation with the tyramide-biotin complex (TSA Plus Biotin Kit, PerkinElmer) at the dilution of 1:75 in Amplified Buffer for 10 min, and finally with HRP-streptavidin (Dako-Cytomation) diluted 1:250 for 20 min. Signal was revealed using diaminobenzadine/hydrogen peroxide (DAB) as a chromogen substrate for 5 min (Dako-Cytomation). TIF images of antibodyand Fast Green FCF-stained slides were analyzed using the Microvigene software (VigeneTech) to extract numeric intensity protein values from the array images.

# Production of Lentiviral Particles and Infection of Cell Lines

To knock-down *EPAS1* expression, the pGIPZ lentiviral shRNAmir that targets human *EPAS1* was purchased from Open Biosystems (Thermo Fisher Scientific). We used two different shRNAs against *EPAS1*: V2LHS113750 (RHS4430–98894439) and V2LHS-113750 (RHS4430–98851126). A nonsilencing pGIPZ lentiviral shRNAmir was used as the control (RHS4346). Lentiviral particles production and in vitro transduction was performed as described.<sup>5</sup>

# **Experimental Design and Statistical Evaluation**

We have analyzed the proteins differentially represented between SHSY5Y cells transfected with empty vector pcDNA and SHSY5Y cells stable overexpressing HIF-2 $\alpha$  protein. We have used three different replicates for each experimental point for DIGE analysis; DIGE data were subjected to the ANOVA test. For phosphoproteomic analysis, we assayed two different HIF- $2\alpha$  and pcDNA clones for each experimental point. Moreover, we used the cells silenced for the HIF- $2\alpha$  coding gene (*EPAS1*) given the sensitivity of pathways balance activation/inhibition in the cells. Statistical analyses were performed with R (www.r-project.org). In particular, identification of potential differences in protein expression was obtained by using the Welch *t* test and considered significant when *p* value <0.05. Comparison between HIF- $2\alpha$ -overexpressing cell clones and relative control cells was



**Figure 1.** Proteomic data obtained by comparing SHSY5Y-HIF- $2\alpha$ -overexpressing cells with respect to SHSY5Y-pcDNA counterparts. Western blotting was performed to test the cross-contamination of cytosolic (lane 1) and nuclear (lane 2) protein extracts from the SHSY5Y-HIF- $2\alpha$  cells (A). Isoelectric focusing on SHSY5Y-HIF- $2\alpha$  and SHSY5Y-pcDNA protein extracts was performed on immobilized pH gradient IPG gel strip, NL pH 3–11; proteins were further separated by 11% SDS-PAGE in the second dimension. Differentially represented spots that were picked-up on the preparative gel for further protein identification analysis (B). Identified proteins were classified using the DAVID 2.1 beta annotation system. The Fisher exact test was used to determine the statistically significance of protein-enrichment in annotation terms. The functional categories and pathways are sorted by *p* value  $(-\log(P))$ . The category terms and the number of proteins are reported on the *Y* axis (C).

performed by considering the whole expression profile of specific pathways and *p* values generated using global test applying 5000 permutations.<sup>19</sup> Hierarchical clustering analysis was performed using Eucledian distance among protein expression and Ward method clustering. Finally, levelplot form lattice package (R Biocoductor) was used to highlight the levels of relative protein expression between HIF- $2\alpha$ -silenced and -overexpressing cells according to selected pathways.

#### HIF-2 $\alpha$ Proteome Signature

K-mean clustering was performed using default parameters by methods implemented in program R2 (http://r2.amc.nl). The probability of overall survival (OS) and event-free survival (EFS) was calculated using the Kaplan–Meier method, and the significance of the difference between Kaplan–Meier curves was calculated by the log-rank test (http://r2.amc.nl). The Cox regression model was used to test for the independent predictive ability of the HIF-2 $\alpha$  proteome signature after the adjustment for other significant factors: MYCN amplification, age, and (International Neuroblastoma Staging System) INSS stages.

# RESULTS

# 2D-DIGE Highlights Differentially Represented Proteins as a Result of HIF-2 $\alpha$ Overexpression in SHSY5Y NB Cells

SHSY5Y-HIF-2 $\alpha$ -overexpressing cells and SHSY5Y-pcDNA cells were obtained as previously reported.<sup>15</sup> HIF-2 $\alpha$  induction on protein and mRNA levels in SHSY5Y cells is shown in Figure S1. The functional characterization of these clones showed that

HIF-2 $\alpha$  overexpression enhances the aggressive features of NB cells. Here we explored the molecular mechanisms that might generate the aggressive behavior mediated by HIF-2 $\alpha$ . To this purpose, the cellular proteome was divided in two different cellular fractions, enriched in either cytosolic or nuclear proteins.<sup>16</sup> We checked the quality of these fractions by Western blotting using specific markers, namely, the nuclear protein lamin  $\beta$  (LM  $\!\beta)$  and the cytosolic protein GAPDH. In fact, LM  $\!\beta$  is mostly detected in the nuclear fraction, whereas GAPDH generally occurs in the cytosolic counterpart and, at lower levels, in the nucleus. We verified that this nuclear fraction also contained mitochondrial, lysosomal and Golgi subcellular compartments, as evidenced by positive staining for the corresponding marker cytochrome P450 reductase, lysosomeassociated membrane glycoprotein 2 (LAMP2), and Golgi reassembly stacking protein of 55 kDa (GRASP55), respectively (Figure 1A). The nuclear fraction from SHSY5Y-HIF-2 $\alpha$  and SHSY5Y-pcDNA cells was then considered for further experiments.

Proteomic changes associated with HIF-2 $\alpha$  overexpression were analyzed using 2D-DIGE. To increase biological and statistical significance of the results, we prepared protein extracts from three independent SHSY5Y-HIF-2 $\alpha$  and SHSY5Y-pcDNA cell cultures; they were labeled with either Cy3 or Cy5 fluorescent dyes according to the scheme shown in Table S3. Each Cy3/Cy5-labeled sample pair was comixed with a Cy2labeled pooled standard sample containing an equal amount of the six samples; Cy2/Cy3/Cy5-labeled samples run together on

l by	
tified	
dent	
I pu	
GE a	
-DI(	
y 2D	
ed b	
educ	
No Do	
on, <sup>j</sup>	
aris	
omp	
ell C	
IA C	
CDN	
SY-p	
HSY	
sus S	
vers	
sing	)
three	
er-Ex	
3V0-X	
(F-20	
IH-Y	
SYS	
e SH	
in th	
iges i	,
Chan	
ive (	
ntitat	
Quai	
ning (	MSa
yhow	WS/I
sins (	I-TLU
Prote	ESI-I
; 1. F	LC-I
ble	JO.

Table nanoL	1. Proteins Showing Quantitativ C-ESI-LIT-MS/MS <sup>a</sup>	re Changes in the SHSY5Y-HIF-2 $\alpha$ -over-Expressing versus	SHSY5Y-pcDN	VA Cell Co	mparison, <sup>1</sup>	As Deduced by 2D-I	DIGE and	Identified by
spot	NCBI code	description	identification score	peptides	unique peptides	sequence coverage (%)	fold 2D- DIGE	gene symbol
214	gil62022572lgblAAH50564.1l	SW1/SNF related, matrix associated, actin-dependent regulator of chromatin	229	6	6	5.6	-1.25	SMARCC1
398	gil3202000 gb AAC19382.1	scaffold attachment factor A	457	12	10	10.9	2.23	HNRNPU
401	gil119569943 gb EAW49558.1	chondroitin sulfate proteoglycan 6 (bamacan), isoform CRA_b	484	10	10	10.8	2.36	SMC3
417	gil999380 gb AAB34405.1	mitosis-specific chromosome segregation protein SMC1 homologue	272	s	5	4.9	4.12	<b>SMC1A</b>
485	gil23342633lemblCAD48681.1l	neurolysin, mitochondrial	227	S	S	9.6	-8.18	n.a.
503	gil516764ldbjlBAA04654.1l	motor protein	254	S	S	9.4	-17.69	HMP
510	gil292059 gb AAA67526.1	MTHSP75	849	16	15	30.8	-10.75	HSPA9
	gil16306859lgblAAH06551.1l	lamin B2	372	7	7	13.8		LMNB2
529	gil347134lgblAAA20683.1l	succinate dehydrogenase flavoprotein subunit	471	10	6	14.2	2.01	SDHA
	gil34228lemblCAA27173.1l	lamin isoform A-delta50	383	8	8	14.7		LMNA
552	gil292059 gb AAA67526.1	MTHSP75	1551	31	26	48.2	1.89	HSPA9
	gil32467lemblCAA68445.1l	71 kDa heat shock cognate protein	474	10	10	19.3		HSPA8
	gil16306859 gb AAH06551.1	lamin B2	435	8	8	15.7		LMNB2
	gil119530lsplP13667.2l	protein disulfide-isomerase A4	323	6	6	12.6		PDIA4
556	gil292059 gb AAA67526.1	MTHSP75	1250	27	23	44.3	2.25	HSPA9
	gil32467lemblCAA68445.1l	71 kDa heat shock cognate protein	1147	27	23	41.2		HSPA8
	gil16306859 gb AAH06551.1	lamin B2	478	6	6	15.5		LMNB2
	gil119530lsplP13667.2l	protein disulfide-isomerase A4	422	6	6	17.2		PDIA4
	gil188492lgblAAA63228.1l	heat shock-induced protein	329	7	7	15.1		HSPAIL
577	gil62087562ldbjlBAD92228.1l	succinate dehydrogenase complex, subunit A, flavoprotein precursor variant	588	12	10	22.1	3.01	SDHA
583	gil347134 gb AAA20683.1	succinate dehydrogenase flavoprotein subunit	807	16	16	30.7	3.38	SDHA
594	gil130781lsplP09874.4l	poly [ADP-ribose] polymerase 1	279	S	S	6.8	3.09	PARP1
603	gil6470150lgblAAF13605.1l AF188611 1	BiP protein	315	6	6	13.3	-8.02	HSPA5
604	gil6470150lgblAAF13605.1l AF188611 1	BiP protein	418	8	8	15.5	-13.2	HSPA5
		ATP synthase subunit beta, mitochondrial	361	7	7	16.6		ATP5B
605	gil32467lemblCAA68445.1l	71 kDa heat shock cognate protein	1317	36	26	44.1	2.18	HSPA8
	gil16306859lgblAAH06551.1l	lamin B2	1214	25	22	35		LMNB2
	gil15341906 gb AAH13138.1	ATPase, H <sup>+</sup> transporting, lysosomal 70 kDa, V1 subunit A	454	11	10	23.5		ATP6V1A
	gil188488lgblAAA63226.1l	heat shock-induced protein	451	8	8	15.8		HSPAIA
	gil189053456ldbjlBAG35622.1l	heat shock 70 kDa protein 6	243	6	s	11.4		HSPA6
608	gil6470150 gb AAF13605.1  AF188611_1	BiP protein	214	6	S	10.8	-12.43	HSPA5
609	gil16306859 gb AAH06551.1	lamin B2	1478	43	30	44.5	2.77	LMNB2
	gil188488lgblAAA63226.1l	heat shock-induced protein	612	17	13	23.4		HSPAIA
610	gil4529893lgblAAD21816.1l	HSP70-1	1195	44	25	39.2	3.39	HSPAIA
	gil194388088ldbjlBAG65428.1l	heat shock 70 kDa protein 1A/1B	1147	43	24	40.4		HSPAIA
	gil16306859lgblAAH06551.1l	lamin B2	476	10	10	18.7		LMNB2
	gil35360lemblCAA68787.1l	PDC-E2 precursor	387	6	8	15.4		DLAT

continued	
Ι.	
Table	

			identification		unique	sequence coverage	fold 2D-	
spot	NCBI code	description	score	peptides	peptides	(%)	DIGE	gene symbol
663	gil135538lsplP17987.1l	T-complex protein 1 subunit alpha	466	8	8	17.1	2.64	TCP1
668	gil38458lemblCAA50283.1l	PTB-associated splicing factor	304	7	7	11.7	-1.36	SFPQ
671	gil37545lemblCAA45409.1l	splicing factor U2AF	196	6	4	14.5	1.74	U2AF2
689	gil129379 splP10809.2	60 kDa heat shock protein, mitochondrial	705	13	12	28.3	2.85	<b>HSPD1</b>
	gil241478 gblAAB20770.1	heterogeneous nuclear ribonucleoprotein complex K	390	6	8	23.1		HNRNPK
	gil37850lemblCAA39600.1l	vimentin	347	7	7	18.5		MIN
669	gil129379 splP10809.2	60 kDa heat shock protein, mitochondrial	1004	23	18	40.8	2.33	HSPD1
	gil241478 gb AAB20770.1	heterogeneous nuclear ribonucleoprotein complex K	525	14	10	24.8		HNRNPK
840	gil6841066 gb AAF28888.1  AF123303_1	calcium-binding transporter	235	S	4	12.7	-4.01	SLC25A24
895	gil33150622lgblAAP97189.1l AF087890_1	beta-succinyl CoA synthetase	592	15	12	36.5	3.6	SUCLA2
868	gil901998 gb AAA70033.1	TAR DNA-binding protein-43	341	7	7	21.3	-8.03	TARDBP
906	gil34138lemblCAA68809.1l	ornithine aminotransferase, mitochondrial isoform 1 precursor	413	6	8	23.7	-5.88	OAT
	gil45710075lgblAAH14519.1l	solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24	488	6	~	23.3		SLC25A24
	gil15679945lgblAAH14279.1l	vesicle amine transport protein 1 homologue (T. californica)	353	7	6	21.9		VAT1
913	gil49457530lemblCAG47064.1l	CKB	576	14	6	30.7	-11.61	CKB
	gil28252lemblCAA25099.1l	actin, cytoplasmic 1	243	8	S	18.9		ACTB
976	gil12803583lgblAAH02625.1l	heterogeneous nuclear ribonucleoprotein A/B	398	8	8	28.1	-3.07	HNRNPAB
866	gil12803583lgblAAH02625.1l	heterogeneous nuclear ribonucleoprotein A/B	496	11	6	25.3	-3.34	HNRNPAB
1011	gil28422556lgblAAH47024.1l	succinate-CoA ligase, GDP-forming, beta subunit	624	17	14	38.8	-7.55	SUCLG2
	gil6456118 gb AAF09142.1  AF190167_1	membrane-associated protein SLP-2	555	10	10	38.8		STOML2
	gil546088lgblAAB30320.1l	cytoplasmic antiproteinase	288	5	S	19.9		n.a.
1013	gil34329lemblCAA68701.1l	L-lactate dehydrogenase B chain	209	5	S	19	-15.53	LDHB
1021	gil62089046ldbjlBAD92970.1l	heterogeneous nuclear ribonucleoprotein M isoform a variant	285	5	s	9.6	-2.89	HNRNPM
1066	gil194390304ldbjlBAG61914.1l	heterogeneous nuclear ribonucleoprotein D-like isoform a	340	7	7	30.3	-3.58	HNRNPDL
	gil762885lgblAAA64895.1l	plakoglobin	256	9	9	9.8		JUP
1083	gil119339lsplP06733.2l	alpha-enolase	850	16	13	41.5	-2.72	<b>ENO1</b>
1088	gil12803583lgblAAH02625.1l	heterogeneous nuclear ribonucleoprotein A/B	277	5	S	24.2	-25.68	HNRNPAB
1001	gil35451lemblCAA50197.1l	serine/threonine specific protein phosphatase	210	5	S	18.5	-2.7	n.a.
1092	gil9836652ldbjlBAB11885.1l	BSCv	326	7	9	18.2	-20.95	APMAP
	gil131467lsplP18031.1l	tyrosine-protein phosphatase nonreceptor type 1	267	S	S	14.5		PTPN1
1093	gil5542020lgblAAD45179.1lL32610_1	ribonucleoprotein	266	5	S	19.1	-18.1	n.a.
1217	gil682748ldbjlBAA08389.1l	antioxidant protein 1	356	11	8	28.5	3.97	PRDX3
1220	gil799381lgblAAB95175.1l	antioxidant enzyme AOE37-2	369	8	7	32.1	3.77	PRDX4
1289	gil1922287lemblCAA66808.1l	enoyl-CoA hydratase	683	16	11	39.3	-7.88	<b>ECHS1</b>
1387	gil2076717lgblAACS1280.1l	glutathione S-transferase	490	11	8	52.4	-3.07	GSTP1
<sup>a</sup> Spot r ascertai	umber, NCBI accession, protein nam ned as reported in the Experimental	te, Mascot score, number of assigned and assigned unique peptides Procedures. n.a., not available.	s, sequence cover	ıge (%), rela	tive fold chai	ige, and gene symbol :	are listed. F	old change was



**Figure 2.** Validation of 2D-DIGE/nanoLC-ESI-LIT-MS/MS data. Western blot analysis of selected proteins was performed on the nuclear fraction from SHSY5Y-HIF-2 $\alpha$  and SHSY5Y-pcDNA cells. H3 was used as the loading control (A). Protein bands were quantified by densitometry. The bar graph shows the integral optic density (IOD) value for each band, normalized with respect to H3 expression (B). Oil red staining images of SHSYSY-HIF-2 $\alpha$  and SHSY5Y-pcDNA cells. The arrows indicate the lipid accumulation (C). Metabolic reactions altered by HIF-2 $\alpha$  overexpression (D).

the same gel. For each gel, the Cy3, Cy5, and Cy2 images were imported into the DeCyder DIA module and analyzed with the BVA module of DeCyder software to reveal constant and differentially represented protein spots (see Experimental Procedures for details). Approximately, 1390 protein spots were detected in the SHSY5Y proteomic maps. They were then filtered for fold changes >1.3 or <1.3 (HIF-2 $\alpha$  vs pcDNA) and p value < 0.05 (Student's paired t test) The analysis allowed us to find 53 statistically relevant and differentially represented spots, whose position on the gel is shown in Figure 1B. In particular, 21 spots were over-represented and 32 spots were underrepresented. The same software modules were also used to match the Cy2 image selected as the master image with the counterpart from a preparative gel obtained by combining all cellular extracts. Corresponding spots from the latter gel were excised, in-gel digested with trypsin, and subjected to nanoLC-ESI-LIT-MS/MS analysis for protein identification. Mass spectrometric analysis identified 49 proteins in 44 spots (Table 1). In several cases, different proteins comigrated in the same spot; in other cases, the same protein occurred in different spots as result of eventual post-translational modifications. In this study, we were not able to determine the identities of the protein components of the other nine differentially represented spots. Identified proteins were then classified according to indicated descriptors for biological processes and molecular pathways; most of them were associated with cellular metabolism, RNA processing/splicing control, and cell death (Figure 1C). The hypothesis that aggressive tumors have an abnormal cellular metabolism was also supported by gene ontology analysis on NB gene expression microarray data sets. As shown in the Supporting Information (Figure S2) "primary metabolic process" and

"macromolecule metabolic process" were the more represented biological processes in relapse patient group.

# Validation of Differentially Represented Proteins and Metabolic Implications

We validated the differential (SHSY5Y-HIF-2 $\alpha$  vs -pcDNA) representation pattern of a dozen of the proteins highlighted by 2D-DIGE analysis by Western blotting (Figure 2A, Table S1). Densitometric analysis of protein bands demonstrated proteins representation as result of HIF-2 $\alpha$  overexpression in NB cells (Figure 2B). In particular, we verified that DLAT, a component of the pyruvate dehydrogenase (PDH) complex, is overrepresented as result of HIF-2 $\alpha$  overexpression. To further assess PDH complex regulation, we also investigated the representation of pyruvate dehydrogenase (lipoamide)  $\beta$ (PDHB) subunit in SHSY5Y-HIF-2 $\alpha$  and SHSY5Y-pcDNA cells by Western blotting. These results highlight that HIF-2 $\alpha$ overexpression induces metabolic changes in NB cells that lead to an increment of pyruvate and acetyl-CoA; this condition may ultimately conduce to cellular fatty acid storage. Accumulation of fatty acids in HIF-2 $\alpha$ -overexpressing cells was also supported by the down-representation of the fatty acid  $\beta$ -oxidation enzyme ECHS1 (2D-DIGE data-spot 1289). This metabolic condition was finally assessed by comparative oil red staining of SHSY5Y-HIF-2 $\alpha$  and -pcDNA cells, which demonstrated an increase in fat droplets in NB cells as a result of HIF-2 $\alpha$  overexpression (Figure 2C,D).

The differential representation patterns of these HIF- $2\alpha$  targets were validated in NB cells silenced for HIF- $2\alpha$  expression. In particular, SHSY5Y and SKNBE2c cells were infected with lentiviral particles to silence the expression of *EPAS1* (Figure



**Figure 3.** RPPA data of HIF-2 $\alpha$ -silenced and HIF-2 $\alpha$ -overexpressing cells. Level plot showing *p* values generated by the comparison of HIF-2 $\alpha$  transgenic cell clones with their relative controls for the expression/activation of 79 proteins, representative of JAK/STAT, NFKB, RAS/MAPK, SRC, WNT, AMPK, PI3K/AKT signaling pathways, apoptosis, and cell cycle processes (A). Table showing pathway global test *p* values obtained for RAS/MAPK, cell cycle, WNT, and PI3K/AKT pathways for each considered comparison; \*\**p* < 0.05, \*0.05 < *p* < 0.1 (B). Level plot showing relative expression of proteins selected from global test analysis for each (RAS/MAPK, cell cycle, WNT, and PI3K/AKT) significant pathway analyzed (C). Heat map showing relative expression of proteins from selected pathways and clustering analysis (D). Western blot analysis of RB (S780), cyclin-E, Pan-RAS, p44/42 MAPK(Erk1/2) (T202/Y204), LEF1, AKT (S473), S6 ribosomal protein (S235/236), PDK1 (S241) proteins performed in SHSYSY-shEPAS1 and SHSYSY-HIF-2 $\alpha$  cell clones, and relative control cells.  $\beta$ -Actin expression has been used as loading control (E). Two clones (HIF-2 $\alpha$ \_A and HIF-2 $\alpha$  B) of SHSYSY cells were engineered to overexpress HIF-2 $\alpha$ .



**Figure 4.** HIF-2 $\alpha$  proteomic signature in NB patients. K-means clustering was used to subdivide gene expression data of freely available 498 primary NB tumors of all stages (SEQC data set) in two patients groups with high (POS) or low (NEG) activity of the HIF-2 $\alpha$  proteome-gene set signature (A). Kaplan-Maier analysis for overall survival and relapse-free survival rates in patients with MYCN single copy (SEQC data set) grouped for high (POS) or low (NEG) activity of the HIF-2 $\alpha$  proteome-gene set signature (B).

S1). As shown in the Supporting Information (Figure S3), the expression of HIF-2 $\alpha$  targets is not strongly modified or is unvaried upon *EPAS1* silencing (shEPAS1 vs -shCTR). However, protein expressions in silenced cells (shEPAS1 vs shCTR) are inverse with respect to expression observed in HIF- $2\alpha$ -overexpressing cells (HIF- $2\alpha$  vs pcDNA). These findings suggest that the identified targets are regulated by downstream effects of HIF- $2\alpha$  overexpression. The down regulation of GSTP1 is convergent in HIF- $2\alpha$ -overexpressing clones and in *EPAS1*-silenced cells. GSTP1 is a detoxification enzyme that plays an important role in neoplastic cells. On the contrary, GSTP1 silencing is a common early event in carcinogenesis, frequently caused by promoter hypermethylation.<sup>21</sup> Our finding suggests that HIF- $2\alpha$  peculiarity acts differently in the same cells in response to diverse stimuli.

# RPPA Analysis of Signaling Pathways Activated Following HIF-2 $\alpha$ Overexpression in SHSY5Y NB Cells

To account for the potential modulation of signaling pathways exerted by HIF-2 $\alpha$ , we performed RPPA analysis of whole cell lysates to evaluate the expression of specific proteins (79 in number) (Table S2), among which 56 ones are activated/ inhibited after phosphorylation at specific residues. For this reason, we compared the phosphorylation events activated/ inhibited by HIF-2 $\alpha$  overexpression with the counterpart induced by HIF-2 $\alpha$  silencing. To avoid false-positive/-negative results, we performed RPPA analysis of SKNBE2c and SHSY5Y NB cells stably knocked-down for *EPAS1* transcript or SHSY5Y NB cells engineered to overexpress HIF-2 $\alpha$ . We observed an increased susceptibility to HIF-2 $\alpha$ -overexpressing or *EPAS1*-tions in perturbated cells (HIF-2 $\alpha$ -overexpressing or *EPAS1*-

silenced cells) rather than alterations of quantitative levels of protein targets.

RPPA data were analyzed and then expression values of each protein were calculated. Protein expression values of HIF-2 $\alpha$ silenced/-overexpressing cells were compared to that of the appropriate control cells (shCTR/pcDNA). Statistical analysis was performed for all comparisons, and obtained p values were arrayed to generate a level-plot showing the potential differential activation of signaling pathways considered. In particular, analyzed proteins were divided for their relation with cellular pathways to cover JAK/STAT, NFKB, RAS/MAPK, SRC, WNT, AMPK, PI3K/AKT signaling pathways, apoptosis, and cell cycle processes (Figure 3A). Because we did not observe any particular recurrence of single differentially represented (phospho) proteins between HIF-2 $\alpha$ -silenced/-overexpressing cells and their relative controls, apart for ERK1/2 and AKT phosphorylation, we reanalyzed data by performing a pathway global test, taking into account the overall expression of all proteins belonging to a determined signaling pathway. As a result, RAS/MAPK, Wnt, and PI3K/AKT pathways showed a significant (p value <0.05) under-activation upon HIF-2 $\alpha$ silencing in at least one comparison (Figure 3B); conversely, RAS/MAPK, Wnt, and PI3K/AKT, with the addition of cell cycle pathways, were all overactivated in at least one HIF-2 $\alpha$ overexpressing cell clone (Figure 3B). Of note, although not all global tests resulted to be significant in every comparison we performed, relative expression of proteins (graphed as level plot in Figure 3C) showed a clear modulation of selected pathways in HIF-2 $\alpha$ -silenced and -overexpressing cells. Importantly, hierarchical unsupervised analysis showed that the expression value of proteins belonging to the selected pathways was sufficient to

completely identify HIF-2 $\alpha$ -silenced and - overexpressing cells (Figure 3D), thus underlining the potential involvement of RAS/MAPK, cell cycle, Wnt, and PI3K/AKT pathways as downstream effectors of HIF-2 $\alpha$  activation. Recently HIF-2 $\alpha$  has been shown as a target of mTORC2.<sup>22</sup> We verified that upon mTOR inhibition in SHSY5Y pcDNA and HIF-2 $\alpha$  clones endogenous HIF-2 $\alpha$  mRNA levels decreased but ectopic HIF-2 $\alpha$  mRNA expression did not. This suggests that HIF-2 $\alpha$  is a direct transcriptional target of mTORC in SHSY5Y and HIF-2 $\alpha$  overexpression might activate PI3K-pathway by promoting an autocrine loop (Figure S4).

The identified differentially activated pathways may be considered as the key regulators of fundamental cancer cell features, such as survival, differentiation, proliferation, and cell metabolism, providing a rationale to the above-described differential representation of proteins, as identified by 2D-DIGE analysis.

Interestingly, phosho-FAK, which is involved in cell migration and motility, was overactivated in HIF-2 $\alpha$ -overexpressing cells (Figure 3A), suggesting its potential involvement in sustaining HIF-2 $\alpha$ -mediated pro-cancerous effects, as reported above.

To validate our RPPA data, we performed Western blot analysis for RB (S780), cyclin-E, PAN-RAS, Erk1/2 (T202/ Y204), LEF1, AKT (S473), S6 ribosomal protein, and PDK1 (S241) on HIF-2 $\alpha$ -silenced/-overexpressing SHSYSY cells (Figure 3E), confirming previous results on their inhibition/ activation (Figure 3A).

#### Prognostic Value of the HIF-2 $\alpha$ Proteomic Signature

We speculated that the gene set codifying for the proteins differentially represented as result of HIF- $2\alpha$  expression may form a signature reflecting the aggressive features in NB (Table S4). The proteome-signature proposed for the stratification of NB patients with unfavorable outcome consists of the genes listed in Table 1.

As a first analysis of this signature, we investigated the prognostic value of the HIF-2 $\alpha$  proteome gene set. To this purpose, we used K-means clustering to subdivide the freely available gene expression data of 498 primary NB tumors at all stages (accession no. GSE62564) in two groups, having high or low activity of the HIF-2 $\alpha$  proteome-gene set signature (Figure 4). One cluster of 157 tumors included the most high-risk samples (Table S4) and showed high expression of up-regulated genes and low expression of down-regulated genes; accordingly, it was named HIF-2 $\alpha$  proteome-POS. Another cluster of 341 NB tumors included most of the low-risk samples (Table S4), having low expression of up-regulated genes and high expression of down-regulated genes; it was designated as HIF-2 $\alpha$  proteome-NEG. Kaplan-Meier analysis of the two clusters showed that tumors with a HIF-2 $\alpha$  proteome-POS signature conferred an extremely poor prognosis (log-rank test OS  $p = 3.7 \times 10^{-33}$ , EFS  $p = 3.9 \times 10^{-24}$ ) (Figure 4A). Amplification of MYCN is an established marker for NB poor prognosis<sup>11</sup> (Figure S2). HIF-2 $\alpha$ proteome-POS signature conferred a poor prognosis independently from MYCN amplification, as observed in patients with MYCN single copy (OS  $p = 2.1 \times 10^{-17}$ , EFS  $p = 7.9 \times 10^{-16}$ ) (Figure 4B). Furthermore, to test whether the HIF-2 $\alpha$  proteoma signature is an independent prognostic factor in the NB samples, we performed multivariate Cox regression analysis of available prognostic factors, including the HIF-2 $\alpha$  proteoma signature, age at diagnosis, INSS stage, and MYCN status. The HIF-2 $\alpha$ proteome signature turned out to be the most significant prognostic marker in addition to age, INSS stage, and MYCN status (Table S5).

#### DISCUSSION

NB is a heterogeneous and complex tumor whose development has not been completely elucidated. Several clinical studies demonstrated that HIF-2 $\alpha$  correlates with NB advanced clinical stage and poor prognosis. We have recently reported that HIF-2 $\alpha$ mRNA expression is correlated to metastatic NB potential and HIF-2 $\alpha$  protein expression enhances pro-invading ability in NB cells.<sup>5,15</sup>

HIF-2 $\alpha$  response to various stimuli is different in organs and cancers.<sup>9</sup> In this study, we have distinguished specific markers/ pathways activated by HIF-2 $\alpha$  in NB progression. We verified that cellular metabolism, RNA processing/splicing control, and cell death represent the most relevant biological processes in support of aggressive tumor phenotype and might be important for successful therapy. A shift in global splicing regulation has been previously reported in high-risk NB tumors.<sup>23</sup> In the cellular system under investigation, we observed: (i) an overrepresentation of the heterogeneous nuclear ribonucleoprotein (hnRNP)K, which is known to promote metastasis in vitro and in vivo;<sup>24</sup> (ii) a down-representation of hnRNPM, whose restricted activity promotes breast cancer metastasis via alternative splicing;<sup>25</sup> (iii) an over-representation of hnRNPU, which can modulate WT1 transcription activation in Wilm's tumors;<sup>26</sup> and (iv) an over-representation of heat shock proteins HSPA8 and HSPA1A, which have been verified as poor prognosis signals in some other cancers for the regulation and stability of oncotranscription factors.<sup>27</sup> Coordinating splicing factors may have a role or might act in opposite manners in other cancers. Understanding how HIF-2 $\alpha$  may induce NB splicesome shift, contributing to more aggressive phenotype, can lead to the development of a new class of anticancer therapeuticsalternative splicing inhibitors.

The altered metabolism has been established as one of the hallmarks of cancer over the last decades.<sup>28</sup> We further confirmed the association of the carbon metabolism to malignancy by observing the correlation of metabolic processes to NB relapse in two patient cohorts. In HIF-2 $\alpha$ -overexpressing cells, we observed an increased representation of pyruvate dehydrogenase complex (PDH), which catalyzes the conversion of pyruvate to acetylcoenzyme A (acetyl-CoA). In addition, we verified augmented levels of dihydrolipoamide S-acetyltransferase (DLAT), a component of the PDH complex, which was previously observed to regulate cellular metabolism and mitochondrial functions.<sup>25</sup> Acetyl-CoA resources may also be provided by inhibition of fatty acid oxidation consequently to the decrement of enoyl CoA hydratase (ECHS1). Thus we might hypothesize that HIF-2 $\alpha$ , and not hypoxia, drives NB cell onco-progression through the block of tricarboxylic acid cycle (TCA) and the increment of fatty acids synthesis. Acetyl-CoA may also impose an increment of acetate, which regulates the interaction of HIF-2 $\alpha$  with its selective coactivator to the promoter of HIF-2 $\alpha$  target genes or tumor progression genes.<sup>30</sup> Furthermore, a pseudohypoxic response that is conveyed by HIF-s is observed. In effect, the increment of succinate dehydrogenase (SDH) and succinate CoA ligase (SUCLG2) may be responsible for the increment of succinate or fumarate, whose accumulation in mitochondria inhibits a family of prolyl hydroxylase enzymes (PHDs).<sup>31</sup> In addition, the suppressed expression of LDHB (lactate dehydrogenase B) may lead to lactate accumulation and oxidative metabolism increment, as observed in pancreatic cancers.<sup>32</sup>

There are some approved drugs directed toward cancer metabolism targets. For instance, glycolytic inhibitors, such as GLUT1 inhibitor and 2-deoxyglucose, underwent clinical trials.<sup>33</sup> Most cancer cell type are addicted to fatty acids, which they require for membrane phospholipid synthesis, signaling purpose, and energy production. The deployment of potential inhibitors to target clinically this facet of tumor metabolism is still under consideration.<sup>34</sup> We suggest that the administration of metabolic inhibitors in HIF-2 $\alpha$  positive tumors fosters an unsupportable conflation of growth promotion and substrate deficiency, with subsequent metabolic catastrophe. Intensive research in recent years has endeavored to determine how the metabolic activity of tumors is regulated. Distinguishing intracellular pathways in support of metabolic activity might suggest the use of a combination therapy with the final aim to avoid resistance to metabolic block. PI3K/AKT pathway alteration following HIFs is a known regulator of cancer metabolism and cancer progression.<sup>35</sup> Recently, the WNT signaling pathway has emerged as a regulatory mediator of cancer cell metabolic activities.<sup>36</sup> Additionally, RAS signaling activation is able to enhance glycolysis, TCA cycle, and de novo nucleic acid synthesis by reprogramming the glycolytic and mitochondrial metabolism through the redox balance of NADH.<sup>37</sup> Of note, the RAS-MAPK pathway is essential for HIF-2 $\alpha$  transactivation, and gene pathway mutations may occur in relapsed NB.<sup>38,39</sup> The increased activity or expression of WNT, RAS/MAPK, and PI3K/AKT in our cellular system suggests that these pathways may fine-tune the sensitivity and the intensity of HIF-2 $\alpha$  driving metabolism. Moreover, recent evidence reports that RAS/MAPK and PI3K/AKT pathways converge to the regulation of mRNA nucleocytoplasmic export.<sup>40,41</sup> Nonetheless, the crosstalk (in both directions) between cellular metabolism and mRNA processing still has to be depicted, and targeting in parallel metabolism or RNA splicing pathways is challenging.

Gene signatures identified to predict NB prognosis have shown a limited clinical value. Here we verified that the gene set codifying the proteins differentially represented by HIF- $2\alpha$ overexpression forms a signature reflecting the aggressive features in NB and having a high power of prognosis prediction. In particular, this signature is able to identify the patients with negative outcome, who would benefit from new and more aggressive treatments. Future prospective studies are needed to further consolidate the validity of these data.

# CONCLUSIONS

We have dissected which proteins and pathways are regulated by HIF-2 $\alpha$  in support of the aggressive features acquired by NB cells when this transcription factor is overexpressed. We have speculated that HIF-2 $\alpha$  perturbation leads to an increment of fatty acid storage, which may maintain proliferation and energy production in cancer cells. Clinically targeting this facet of tumor metabolism may inhibit the mechanism for tumor cells to satisfy their strict metabolic requirement. However, the partial inhibition of a pathway may induce the tumor to find a way to evade the metabolic block. For this reason, we investigated the intracellular mediators that may regulate the metabolic activity by means of fine-tuning the sensitivity and intensity of HIF-2 $\alpha$ pathways. The inhibition of deregulated intracellular mediators, such as RAS/MAPK, PI3K/AKT, and WNT, may be relevant for developing more accurate and focused therapy, in combination with antimetabolic drugs or splicing inhibitors. An interesting novelty of the presented approach has been to identify a gene signature able to stratify NB patients in two risk subgroups starting from proteomic analysis. These findings provide the most reliability of a proteomic screening compared with gene expression screening. In conclusion, the presented approach has provided additional markers/pathways to be considered in developing targeted therapy and improving prognosis as an alternative to HIF-2 $\alpha$  in solid tumors. The feasibility to test this proteomic approach to undruggable markers should finally result in the type of progress to avoid undesirable side effects.

# ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jproteo-me.6b00457.

Figure S1. HIF- $2\alpha$  protein and mRNA levels in HIF- $2\alpha$ overexpressing clones and *EPAS1*-silenced clones. Figure S2. Gene Ontology analysis in two cohorts of NB relapsed patients. Figure S3. HIF- $2\alpha$  target proteins expression in *EPAS1*-silenced cells. Figure S4. HIF- $2\alpha$  is a direct transcriptional target of mTORC in SHSY5Y cells. Figure S5. Prognostic value of the HIF- $2\alpha$  proteomic signature. Table S1. Antibodies used for Western Blotting. Table S2. Antibodies used for reverse phase protein array. Table S3. Experimental design of 2D-DIGE. Table S4. Tumor characteristics of two NB gene clusters. Table S5. Multivariate Cox regression analyses. (PDF)

#### AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail: cimminof@ceinge.unina.it. Phone: +39 081 3737 736. Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) (11869) (A.I.); "Fondazione Italiana per la Lotta al Neuroblastoma" (M.C.); OPEN Associazione Oncologica Pediatrica e Neuroblastoma (A.I., M.C.); Fondazione Istituto di Ricerca Pediatrica Città della Speranza and Fondazione CARIPARO (IRP13/05) (G.B.); and Associazione Culturale *DiSciMuS* RFC (Progetto Biologia dei Tumori Ipossici) (N.Z.). F.C. was supported by a Fondazione Umberto Veronesi post-Doc Fellowship. V.S. was supported by a postdoctoral fellowship by AIRC. We are grateful to Dr. Benedetta Accordi from University of Padova for technical help in RPPA setup.

#### REFERENCES

(1) Lu, X.; Kang, Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. *Clin. Cancer Res.* **2010**, *16*, 5928–35.

(2) Zhao, J.; Du, F.; Luo, Y.; Shen, G.; Zheng, F.; Xu, B. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. *Cancer Treat. Rev.* **2015**, *41*, 623–33.

(3) Löfstedt, T.; Fredlund, E.; Holmquist-Mengelbier, L.; Pietras, A.; Ovenberger, M.; Poellinger, L.; Påhlman, S. Hypoxia inducible factor-2alpha in cancer. *Cell Cycle* **2007**, *6*, 919–26.

(4) Nilsson, M. B.; Zage, P. E.; Zeng, L.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Zweidler-McKay, P. A.; Heymach, J. V. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. *Oncogene* **2010**, *29*, 2938–49. (5) Cimmino, F.; Pezone, L.; Avitabile, M.; Acierno, G.; Andolfo, I.; Capasso, M.; Iolascon, A. Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. *Sci. Rep.* **2015**, *5*, 11158.

(6) De Miguel, M. P.; Alcaina, Y.; de la Maza, D. S.; Lopez-Iglesias, P. Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency. *Curr. Mol. Med.* **2015**, *15*, 343–59.

(7) Heddleston, J. M.; Li, Z.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. *Cell Cycle* **2009**, *8*, 3274–84.

(8) Holmquist-Mengelbier, L.; Fredlund, E.; Lofstedt, T.; Noguera, R.; Navarro, S.; Nilsson, H.; Pietras, A.; Vallon-Christersson, J.; Borg, A.; Gradin, K.; Poellinger, L.; Påhlman, S. Recruitment of HIF-1alpha and HIF-2alpha to common targetgenes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. *Cancer Cell* **2006**, *10*, 413–23.

(9) Kim, W. Y.; Perera, S.; Zhou, B.; Carretero, J.; Yeh, J. J.; Heathcote, S. A.; Jackson, A. L.; Nikolinakos, P.; Ospina, B.; Naumov, G.; Brandstetter, K. A.; Weigman, V. J.; Zaghlul, S.; Hayes, D. N.; Padera, R. F.; Heymach, J. V.; Kung, A. L.; Sharpless, N. E.; Kaelin, W. G.; Wong, K. K. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. *J. Clin. Invest.* **2009**, *119*, 2160–70.

(10) Burroughs, S. K.; Kaluz, S.; Wang, D.; Wang, K.; Van Meir, E. G.; Wang, B. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. *Future Med. Chem.* **2013**, *5*, 553–72.

(11) Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. **2010**, 362, 2202–11.

(12) Mosse, Y. P.; Lim, M. S.; Voss, S. D.; Wilner, K.; Ruffner, K.; Laliberte, J.; Rolland, D.; Balis, F. M.; Maris, J. M.; Weigel, B. J.; Ingle, A. M.; Ahern, C.; Adamson, P. C.; Blaney, S. M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. *Lancet Oncol.* **2013**, *14*, 472.

(13) Yu, A. L.; Gilman, A. L.; Ozkaynak, M. F.; London, W. B.; Kreissman, S. G.; Chen, H. X.; Smith, M.; Anderson, B.; Villablanca, J. G.; Matthay, K. K.; Shimada, H.; Grupp, S. A.; Seeger, R.; Reynolds, C. P.; Buxton, A.; Reisfeld, R. A.; Gillies, S. D.; Cohn, S. L.; Maris, J. M.; Sondel, P. M. Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N. Engl. J. Med.* **2010**, 363, 1324.

(14) Mohlin, S.; Hamidian, A.; Påhlman, S. HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts. *Neoplasia* **2013**, *15*, 328–34.

(15) Cimmino, F.; Avitabile, M.; Pezone, L.; Scalia, G.; Montanaro, D.; Andreozzi, M.; Terracciano, L.; Iolascon, A.; Capasso, M. CD55 is a HIF-2 $\alpha$  marker with anti-adhesive and pro-invading properties in neuroblastoma. *Oncogenesis* **2016**, *5*, e212.

(16) Cimmino, F.; Spano, D.; Capasso, M.; Zambrano, N.; Russo, R.; Zollo, M.; Iolascon, A. Comparative proteomic expression profile in alltrans retinoic acid differentiated neuroblastoma cell line. *J. Proteome Res.* **2007**, *6*, 2550–64.

(17) Scippa, G. S.; Rocco, M.; Ialicicco, M.; Trupiano, D.; Viscosi, V.; Di Michele, M.; Arena, S.; Chiatante, D.; Scaloni, A. The proteome of lentil (*Lens culinaris* Medik.) seeds: discriminating between landraces. *Electrophoresis* **2010**, *31*, 497–506.

(18) Buanne, P.; Renzone, G.; Monteleone, F.; Vitale, M.; Monti, S. M.; Sandomenico, A.; Garbi, C.; Montanaro, D.; Accardo, M.; Troncone, G.; Zatovicova, M.; Csaderova, L.; Supuran, C. T.; Pastorekova, S.; Scaloni, A.; De Simone, G.; Zambrano, N. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. *J. Proteome Res.* **2013**, *12*, 282–92.

(19) Persano, L.; Pistollato, F.; Rampazzo, E.; Della Puppa, A.; Abbadi, S.; Frasson, C.; Volpin, F.; Indraccolo, S.; Scienza, R.; Basso, G. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1 $\alpha$  stability and MGMT expression. *Cell Death Dis.* **2012**, *3*, e412.

(20) Goeman, J. J.; van de Geer, S. A.; de Kort, F.; van Houwelingen, H. C. A global test for groups of genes: testing association with a clinical outcome. *Bioinformatics* **2004**, *20*, 93–99.

(21) Schnekenburger, M.; Karius, T.; Diederich, M. Regulation of epigenetic traits of the glutathione S-transferase P1 gene: from detoxification toward cancer prevention and diagnosis. *Front. Pharmacol.* **2014**, DOI: 10.3389/fphar.2014.00170.

(22) Mohlin, S.; Hamidian, A.; von Stedingk, K.; Bridges, E.; Wigerup, C.; Bexell, D.; Påhlman, S. PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. *Cancer Res.* **2015**, *75*, 4617–28.

(23) Guo, X.; Chen, Q. R.; Song, Y. K.; Wei, J. S.; Khan, J. Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status. *BMC Med. Genomics* **2011**, DOI: 10.1186/1755-8794-4-35.

(24) Gao, R.; Yu, Y.; Inoue, A.; Widodo, N.; Kaul, S. C.; Wadhwa, R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. *J. Biol. Chem.* **2013**, *288*, 15046–56.

(25) Xu, Y.; Gao, X. D.; Lee, J. H.; Huang, H.; Tan, H.; Ahn, J.; Reinke, L. M.; Peter, M. E.; Feng, Y.; Gius, D.; Siziopikou, K. P.; Peng, J.; Xiao, X.; Cheng, C. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. *Genes Dev.* **2014**, *28*, 1191–203.

(26) Spraggon, L.; Dudnakova, T.; Slight, J.; Lustig-Yariv, O.; Cotterell, J.; Hastie, N.; Miles, C. hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation. *Oncogene* **2007**, *26*, 1484–91.

(27) Finka, A.; Sharma, S. K.; Goloubinoff, P. Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones. *Front Mol. Biosci.* **2015**, DOI: 10.3389/fmolb.2015.00029.

(28) Yang, H.; Xiong, Y.; Guan, K. Metabolic alteration in tumorigenesis. *Sci. China: Life Sci.* **2013**, *56*, 1067–75.

(29) Chueh, F. Y.; Leong, K. F.; Cronk, R. J.; Venkitachalam, S.; Pabich, S.; Yu, C. L. Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription. *Cell. Signalling* **2011**, *23*, 1170–8.

(30) Chen, R.; Xu, M.; Nagati, J. S.; Hogg, R. T.; Das, A.; Gerard, R. D.; Garcia, J. A. The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment. *PLoS One* **2015**, *10*, e0116515.

(31) King, A.; Selak, M. A.; Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. *Oncogene* **2006**, *25*, 4675–82.

(32) Cui, J.; Quan, M.; Jiang, W.; Hu, H.; Jiao, F.; Li, N.; Jin, Z.; Wang, L.; Wang, Y.; Wang, L. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. *Med. Oncol.* **2015**, DOI: 10.1007/s12032-015-0589-8.

(33) Gautier, E. L.; Westerterp, M.; Bhagwat, N.; Cremers, S.; Shih, A.; Abdel-Wahab, O.; Lütjohann, D.; Randolph, G. J.; Levine, R. L.; Tall, A. R.; Yvan-Charvet, L. HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. *J. Exp. Med.* **2013**, *210*, 339–53.

(34) Kinlaw, W. B.; Baures, P. W.; Lupien, L. E.; Davis, W. L.; Kuemmerle, N. B. Fatty Acids and Breast Cancer: Make them on Site or have them Delivered. *J. Cell. Physiol.* **2016**, *231*, 2128.

(35) Courtnay, R.; Ngo, D. C.; Malik, N.; Ververis, K.; Tortorella, S. M.; Karagiannis, T. C. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. *Mol. Biol. Rep.* **2015**, *42*, 841–51.

(36) Sherwood, V. WNT signaling: an emerging mediator of cancer cell metabolism? *Mol. Cell. Biol.* **2015**, 35, 2.

(37) Chesney, J.; Telang, S. Regulation of glycolytic and mitochondrial metabolism by ras. *Curr. Pharm. Biotechnol.* **2013**, *14*, 251–60.

(38) Conrad, P. W.; Freeman, T. L.; Beitner-Johnson, D.; Millhorn, D. E. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. *J. Biol. Chem.* **1999**, *274*, 33709–13.

(39) Eleveld, T. F.; Oldridge, D. A.; Bernard, V.; Koster, J.; Daage, L. C.; Diskin, S. J.; Schild, L.; Bentahar, N. B.; Bellini, A.; Chicard, M.;

Lapouble, E.; Combaret, V.; Legoix-Né, P.; Michon, J.; Pugh, T. J.; Hart, L. S.; Rader, J.; Attiyeh, E. F.; Wei, J. S.; Zhang, S.; Naranjo, A.; Gastier-Foster, J. M.; Hogarty, M. D.; Asgharzadeh, S.; Smith, M. A.; Guidry Auvil, J. M.; Watkins, T. B.; Zwijnenburg, D. A.; Ebus, M. E.; van Sluis, P.; Hakkert, A.; van Wezel, E.; van der Schoot, C. E.; Westerhout, E. M.; Schulte, J. H.; Tytgat, G. A.; Dolman, M. E.; Janoueix-Lerosey, I.; Gerhard, D. S.; Caron, H. N.; Delattre, O.; Khan, J.; Versteeg, R.; Schleiermacher, G.; Molenaar, J. J.; Maris, J. M. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. *Nat. Genet.* **2015**, *47*, 864.

(40) Topisirovic, I.; Sonenberg, N. mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. *Cold Spring Harbor Symp. Quant. Biol.* **2011**, *76*, 355–67.

(41) Culjkovic, B.; Topisirovic, I.; Skrabanek, L.; Ruiz-Gutierrez, M.; Borden, K. L. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. *J. Cell Biol.* **2005**, *169*, 245–56.